Abstract
Multiple myeloma (MM) is known to cause accelerated osteoclastogenic and increased bone resorption through Receptor Activator of Nuclear Factor Kappa-B Ligand pathway (RANKL). Denosumab, which is a RANKL inhibitor is commonly used in treating hypercalcemia in these patients. Incidence of hypocalcemia is 8-14% after the administration of denosumab in such patient population. We present a case of severe hypocalcemia and hypomagnesemia in a patient with multiple myeloma and CKD after treatment with Denosumab.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
